The val$^{158}$met polymorphism of human catechol-O-methyltransferase (COMT) affects anterior cingulate cortex activation in response to painful laser stimulation by Mobascher, Arian et al.
MOLECULAR PAIN
Mobascher et al. Molecular Pain 2010, 6:32
http://www.molecularpain.com/content/6/1/32
Open AccessR E S E A R C HResearchThe val158met polymorphism of human 
catechol-O-methyltransferase (COMT) affects 
anterior cingulate cortex activation in response to 
painful laser stimulation
Arian Mobascher*1,2, Juergen Brinkmeyer2,3, Holger Thiele4, Mohammad R Toliat4, Michael Steffens5, Tracy Warbrick3, 
Francesco Musso2, Hans-Joerg Wittsack6, Andreas Saleh6, Alfons Schnitzler7 and Georg Winterer3,4
Abstract
Background: Pain is a complex experience with sensory, emotional and cognitive aspects. Genetic and environmental 
factors contribute to pain-related phenotypes such as chronic pain states. Genetic variations in the gene coding for 
catechol-O-methyltransferase (COMT) have been suggested to affect clinical and experimental pain-related 
phenotypes including regional μ-opioid system responses to painful stimulation as measured by ligand-PET (positron 
emission tomography). The functional val158met single nucleotide polymorphism has been most widely studied. 
However, apart from its impact on pain-induced opioid release the effect of this genetic variation on cerebral pain 
processing has not been studied with activation measures such as functional magnetic resonance imaging (fMRI), PET 
or electroencephalography. In the present fMRI study we therefore sought to investigate the impact of the COMT 
val158met polymorphism on the blood oxygen level-dependent (BOLD) response to painful laser stimulation.
Results: 57 subjects were studied. We found that subjects homozygous for the met158 allele exhibit a higher BOLD 
response in the anterior cingulate cortex (ACC), foremost in the mid-cingulate cortex, than carriers of the val158 allele.
Conclusion: This result is in line with previous studies that reported higher pain sensitivity in homozygous met carriers. 
It adds to the current literature in suggesting that this behavioral phenotype may be mediated by, or is at least 
associated with, increased ACC activity. More generally, apart from one report that focused on pain-induced opioid 
release, this is the first functional neuroimaging study showing an effect of the COMT val158met polymorphism on 
cerebral pain processing.
Background
Pain is a multidimensional construct embodying sensory,
affective and cognitive components [1] exhibiting a high
degree of inter-individual variability in clinical and exper-
imental settings [2,3]. Twin studies suggest that genetic
factors contribute to the observed inter-individual differ-
ences in pain-related phenotypes with heritability esti-
mates of up to 70% for clinical pain conditions [2,3] and
up to 60% for sensitivity to certain kinds of experimental
stimuli [4]. In view of the complexity of pain processing
with regard to the neuroanatomical structures/networks
and neurochemical systems involved [5,6], single nucle-
otide polymorphisms (SNPs) in multiple genes can be
expected to contribute to the overall heritability of pain-
related phenotypes.
Brain activity as measured by functional neuroimaging
has been shown to correlate with subjective pain experi-
ence [7-9]. Therefore brain activation measures may
serve as intermediate phenotypes when genetic aspects of
pain behavior are studied. However, only a few studies
have applied functional magnetic resonance imaging
(fMRI) or positron emission tomography (PET) to inves-
tigate the impact of inter-individual genetic differences
on cerebral pain processing [10,11]. One of the few SNPs
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pain measures and brain activity as measured by neu-
roimaging is a common functional variant in the gene
coding for catechol-O-methyltransferase (COMT).
COMT is an enzyme that controls the breakdown of cate-
cholamines in the brain. The COMT val158met SNP
(rs4680) - in which valine is replaced by methionine at
position 158 of the amino acid chain - has been shown to
affect opiate requirements in clinical settings and sensi-
tivity to experimental pain [10,12,13]. Using μ-opoid
receptor ligand-PET, Zubieta et al. also showed that this
SNP affects the activity of the endogenous opioid system
upon painful stimulation. Subjects homozygous for the
met158 allele have been reported to exhibit highest pain
sensitivity with subjects homozygous for the val158 allele
showing the opposite phenotype. On the other hand,
there are also several studies that reported no effect of
this SNP on pain experience [14,15].
Intermediate phenotypes as revealed by neuroimaging
techniques such as fMRI are thought to be more closely
linked to the genetics of a complex behavior and neurop-
sychiatric disorders than the behavior/the disorder itself
[16]. To our knowledge no imaging studies on the impact
of the COMT val158met polymorphism on brain activity
upon painful stimulation have been published - apart
from the molecular imaging study of Zubieta and col-
leagues [10] using μ-opoid receptor ligand-PET. There-
fore, functional studies to assess the impact of the COMT
genotype on cerebral pain processing are warranted. In
the present study, the COMT val158met genotype effect
on the fMRI BOLD (blood-oxygen-level-dependent)
response to painful laser stimulation was investigated.
Results and Discussion
BOLD response to laser stimulation
Voxelwise analysis revealed significant BOLD responses
to laser stimuli in the entire pain matrix including cortical
and subcortical areas such as contralateral primary soma-
tosensory cortex (S1), bilateral secondary somatosensory
cortex (S2), bilateral insula, anterior cingulate cortex
(ACC), precuneus, cerebellum thalamus and brainstem
(see Fig. 1 and Table 1 for detailed information).
Factors determining BOLD activation
Exploratory region-of-interest (ROI) analyses revealed no
significant effects of gender or smoking status on BOLD
activation (mean Z values) in the parietal opercular cor-
tex, the insula, the ACC or the amygdalae (data not
shown). However age was negatively correlated with
mean Z values in all four ROIs (Pearson correlation coef-
ficients: r = -0.401 (ACC), r = -0.450 (S2), r = -0.481
(insula) and r = -0.402 (amygdalae); p < 0.002). The gen-
eral linear model (GLM) multivariate analysis of variance
(MANOVA) revealed a statistically significant COMT
genotype effect on BOLD activation across the four ROIs
(F = 2.794, df = 4, p = 0.035). Subsequent analyses of vari-
ance (ANOVAs) four each ROI showed a significant gen-
otype effect in three out of four ROIs (trend finding in the
bilateral amygdala) with subjects homozygous for the
met158 allele consistently exhibiting higher mean BOLD
activation (see Table 2 for detailed information). When
the ANOVAs were corrected for age, only the genotype
effect on BOLD activation in the ACC remained statisti-
cally significant (F = 6.32; p = 0.015; df = 1). In Fig. 2 the
effect of COMT genotype on ACC activation is shown.
Similar results were obtained, when only the population-
based subsample of N = 47 subjects was analysed (data
not shown).
As the ACC is a large structure in which subregions
serve distinct purposes in cortical pain processing, we
next sought to investigate which subregion(s) of the ACC
were affected by COMT genotype with respect to laser-
induced BOLD activation. The voxel-by-voxel analysis
restricted to the ACC showed that subjects homozygous
for the met158 allele exhibited higher BOLD activation in
the posterior ACC/mid-cingulate cortex (Zmax = 3.37;
MNI coordinates x/y/z: 10/-10/38). See also Fig. 1b.
No correlation between post-hoc pain ratings and
BOLD activation (as measured by mean Z values in the
ROIs) was observed (Pearson correlation coefficients: r =
0.162 (ACC), r = 0.054 (S2), r = 0.096 (insula) and r =
0.181 (amygdalae); p > 0.177). Likewise, no statistically
significant effect of genotype on post-hoc pain ratings
was found (met/met genotype: mean 41.4/SD 14.2; val
carriers: mean 42.4/SD 16.4; F = 0.05; p = 0.824, df = 1).
Discussion
In the present study we sought to investigate the impact
of the COMT val158met single nucleotide polymorphism
on cerebral pain processing as measured by fMRI.
The overall BOLD activation pattern in response to
painful laser stimulation in our study is consistent with
numerous previous imaging studies showing activation of
a distributed network of cortical and subcortical struc-
tures including the core regions of cerebral pain process-
ing (often referred to as the 'pain matrix') such as the
bilateral parietal operculum containing the secondary
somato-sensory cortex (S2), bilateral insula and bilateral
anterior cingulate cortex (ACC)/mid-cingulate cortex
(MCC) [5,6,17].
Subjects homozygous for the met158 allele exhibited a
higher BOLD response to laser stimulation than carriers
of the val158 allele (homozygous and heterozygous val158
carriers combined) in key areas of the 'pain matrix' - i.e.
in S2, the insula the amygdalae and foremost in the ACC.
In the voxel-by-voxel analysis restricted to the ACC we
found the most significant activation difference between
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MCC.
The ACC has been shown to be a key structure of corti-
cal pain processing that is involved in the cognitive/emo-
tional evaluation of pain as well as in antinociception
[5,6,18-21]. Furthermore, Büchel et al. [8] showed that
activation in the posterior ACC/MCC is correlated with
stimulus intensity and pain ratings. Therefore our data
are consistent with previous studies that found an associ-
ation of the COMT met158 allele with higher pain ratings
[10,13] and with altered μ-opioid receptor density and
opioid responses to pain in several brain areas including
the dorsal ACC [10]. Our results add to the current litera-
ture in that they suggest that COMT-dependent ACC/
MCC activity plays a prominent role in mediating sensi-
tivity to pain, possibly due to a reduction of opioid-medi-
ated inhibitory control. However, it needs to be pointed
out that negative findings with regard to the effect of this
SNP on pain-related phenotypes have also been reported
[14,15]. This discrepancy may be explained by sample
heterogeneity, differences in the modality used to elicit
pain and by differences in the behavioral readout. Fur-
thermore it has been suggested that haplotypes that also
include other SNPs in COMT may exert a stronger effect
on pain-related phenotypes [22,23] than the COMT
val158met polymorphism alone. We observed an effect of
COMT genotype on brain activation in the absence of
any behavioral effects (subjective pain ratings). This dis-
crepancy may be explained by different effect sizes of
imaging endophenotypes and behavioral phenotypes
with larger genotype effects on brain activation than on
overt behavior [16,24].
The COMT val158met polymorphism may affect pain
processing in several ways. The met158 allele codes for an
enzyme variant that is less stable at body temperature
leading to higher dopamine levels in the brain, mainly in -
but not restricted to - the (pre)frontal cortex. Dopamine
levels may modulate the activity of the endogenous opi-
oid system indirectly by regulating the neuronal content
of enkephalins [10,25,26]. This could affect activation
measures in brain areas involved in processing and mod-
ulation of painful stimuli and ultimately behavioral pain-
related phenotypes [10]. Alternatively/additionally,
COMT may affect pain processing by decreasing the
metabolism of epinephrine which has also been shown to
modulate pain processing. For instance, Khasar et al. [27]
showed that β2-adrenergic stimulation induces hyperal-
gesia in the rat. Furthermore it has been shown that a
COMT inhibition-induced increase in pain sensitivity is
blocked by beta-adrenergic antagonists [28]. Yet another
alternative may be that the COMT val158met SNP affects
brain activity in response to painful stimulation in a
rather unspecific way: a substantial amount of genetic
imaging papers found an impact of this SNP on brain
activity in various cognitive domains such as attention,
working memory and affective regulation [29]. The geno-
type effect on pain processing that we found in the pres-
ent study may therefore be 'downstream' of a more direct
influence on attention or affect regulation. For instance,
Smolka et al. [30] showed that compared to carriers of the
val allele subjects homozygous for the met allele exhibit
an increased BOLD response to unpleasant pictures in a
partially overlapping network of structures including the
amygdala. Therefore homozygous met carriers may be
more reactive to a variety of negative stimuli including
Table 1: BOLD activation in response to laser stimulation
Region MNI coordinates 
(X Y Z)
Peak 
activation (Z)
R. parietal operculum 62 -24 20 7.68
R. insula 36 24 -4 8.13
R. postcentral gyrus 42 -36 58 3.80
R. amygdala 22 0 -16 5.25
R. precentral gyrus 44 -2 58 6.34
R. (pre)frontal cortex 46 38 2 5.84
L. parietal operculum -58 -24 18 7.12
L. insula -36 20 2 7.94
L. (pre)frontal cortex -38 44 20 4.60
L. amygdala -24 0 -18 4.46
ACC/mid-cingulate 6 12 34 6.56
Precuneus 12 -70 40 5.28
cerebellum -30 -60 -34 5.80
R. thalamus 14 -10 2 6.26
L. thalamus 12 -12 -2 5.23
Midbrain 10 -24 -14 5.95
Brainstem 2 -30 -46 4.92
R = right, L = left
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site of the most significant genotype effect in our study
and a key structure of the pain matrix - was not affected
by COMT genotype in the study by Smolka et al. This
region of the ACC has been implicated in several aspects
of pain processing such as encoding pain- and stimulus
intensity [8]. Furthermore the dorsal ACC has been
shown to be one of the sites of pain-induced opioid
release [19]. In a subsequent paper Zubieta et al. [10]
showed that the COMT val158met polymorphism affects
the μ-opioid response to painful stimulation in the dorsal
ACC. Last, it has been shown that the ACC/MCC is the
main generator of the N2 and P2 laser-evoked potentials
in studies using EEG source localization [31], intracranial
recordings [32] or more recently EEG-informed fMRI
[33]. All this may suggest that the observed effect of
COMT genotype on fMRI BOLD activation is not entirely
unspecific. However, it has recently been shown that
Figure 1 BOLD response to laser stimulation. a) Group average. N = 57 subjects. GLM whole-brain analysis. Second-level mixed-effects FLAME. 
Cluster-corrected threshold Z = 3.5, p = 0.05. Upper row: 3 D surface projection. Lower row: axial slices. R = right. L = left. b) Two-group t-test. COMT-
met/met (N = 19) vs. COMTval carriers (N = 38). Voxel-by-voxel analysis restricted to the anterior cingulate cortex (according to the Harvard Oxford 
atlas). Second-level mixed-effects FLAME. Cluster-corrected threshold Z = 2.3, p = 0.05. Upper row: 3 D surface projection. Lower row: sagittal slices.
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specific [34].
The genetic basis of pain perception and processing has
mostly been studied in clinical settings such as chronic
pain states, post-surgical pain or experimental settings in
which tonic pain models were applied. Correspondingly,
an effect of COMT genotype on pain-related phenotypes
has for instance been shown in cancer patients with
regard to analgesic requirements [12,35] and in experi-
ments in which models of sustained pain such as the
intramuscular injection of hypertonic saline [10]; tonic
heat pain [13] or the temporal summation of thermal pain
were studied [22]. By contrast laser stimulation of the
skin as applied in our study induces phasic pain which is
quite different from tonic pain models or clinical pain
states. An effect of COMT genotype on phasic pain has
not been reported so far. Therefore our findings require
further replication and cannot readily be transferred to
clinical pain states and their genetic basis.
Our study has several limitations. First, our sample
comprised only 9 subjects with COMT val/val genotype, a
number that we considered to low to constitute a separate
group in our genetic fMRI analyses. Thus, we combined
homozygous and heterozygous val158 carriers in one
group which leaves the question of additive vs. dominant/
recessive gene effects unanswered. Second, due to techni-
cal reasons we did not obtain continuous online pain rat-
ings, but only post-hoc ratings which are considered less
accurate. This could explain the lack of a relationship
between pain ratings on one hand and COMT genotype
and fMRI BOLD activation on the other hand. Then
again genotype effects are well known to require compar-
atively large samples to be detected when behavioral
measures and probably even more so subjective measures
like pain ratings are used which is one of the main rea-
sons why intermediate phenotypes like brain activation as
measured by fMRI are studied [16]. Third, our paradigm
did not include a control condition with innoxious stim-
uli. While laser stimulation of the skin provides Aδ and C
fibre-mediated nociceptive-specific input to the brain,
cerebral processing of that input has been shown not to
be pain-specific [34]. Therefore we cannot rule out the
possibility that the observed differences between COMT
genotype groups in the BOLD activation pattern reflect a
more general genotype effect on brain activity especially
as COMT affects several aspects of human behavior
including, attention working memory and emotional reg-
ulation [29]. Lastly, we investigated a rather heteroge-
neous sample, which is reflected by the high impact of
age on BOLD activation measures in our study. Heteroge-
neity of the sample may increase the background variance
in the data diminishing the effect of the genetic variant
that is under investigation [2]. On the other hand, the
genotype effect survived age correction and we found an
impact of the COMT158val/met on ACC/MCC activation
in a sample that was largely selected from a population-
based sample even after age correction. The latter may in
fact be considered a plus with respect to the generaliz-
ability of the results of a genetic imaging study.
Conclusion
To our knowledge, this is the first fMRI study showing an
effect of the COMT val158met polymorphism on brain
activation - mainly in the posterior ACC - in response to
experimental pain. We consider this an important inde-
pendent verification of previous work using a μ-opioid
specific PET ligand that suggested that this SNP affects
the neurobiology of pain processing in related brain
regions. More generally our study provides further evi-
dence that pain-related intermediate phenotypes
revealed by neuroimaging methods such as fMRI may be
a useful concept to study genotype-phenotype relation-
ships in pain research.
Table 2: Impact of COMT genotype on fMRI BOLD activation
Region of Interest Genotype (df = 1)
Met/Met
(Mean Z value/SD)
Val carriers
(Mean Z value/SD)
F p
ACC 1.69/1.75 0.55/1.05 9.447 0.003
Insula 2.29/1.88 1.40/1.08 5.136 0.027
parietal operculum (containing S2) 2.13/1.75 1.36/0.94 4.677 0.035
Amygdalae 1.09/1.48 0.52/0.85 3.507 0.066
Analyses of variance (ANOVAs) with genotype as factor and mean Z values in regions of interest as dependent variables.
df = degrees of freedom; ACC = anterior cingulate cortex; S2 = secondary somatosensory cortex; SD = standard deviation
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Subjects
A total of N = 57 healthy subjects (27 males) with a mean
age of 35.3 (SD 11.1) years were recruited both from a
larger population-based sample that will be described in
more detail elsewhere (Mobascher et al., unpublished
data, N = 47 subjects) and from the environment of the
local university (students or staff, N = 10 subjects).
Because of the small number of subjects homozygous for
the COMT val158 allele (N = 9) - which may be consid-
ered too low for the purposes of genetic fMRI - this group
was combined with the group of heterozygous COMT
val/met carriers for subsequent analyses. Demographic
data for both genotype groups (COMT met/met vs.
COMT val carriers, i.e. COMTval/met + COMTval/val)
are provided in Table 3. Subjects had no history of neuro-
logical or psychiatric disease and did not take any medi-
cation that could affect the experiment. To minimize
potential confounding effects of the female hormonal
cycle on pain processing [36,37] all female subjects were
investigated during the follicular phase of the menstrual
cycle. All subjects had normal pain thresholds (350-500
mJ) as determined prior to the imaging experiment using
a series of laser stimuli increasing in steps of 50 mJ from
200 to 600 mJ. Subjects were asked to report the point at
which the sensation could be described as painful. This
procedure was repeated with decreasing steps of 50 mJ
from 600 to 200 mJ with subjects reporting when the sen-
sation was no longer painful. The mean of these two val-
ues was taken as pain threshold. Subjects gave written
informed consent to participate in the study. The study
was conducted in compliance with the declaration of Hel-
sinki and was approved by the local ethics committee.
Genotyping
The COMT val158 met polymorphism rs4680 was geno-
typed by ABI TaqMan® technology [38]. Several DNA rep-
licates, reference DNA samples and negative controls
without DNA were included to ensure the accuracy of the
SNP genotyping assay. TaqMan® probes and primers were
obtained from the Assay-on-Demand genotyping prod-
uct provided by Applied Biosystems (Applied Biosystems,
Foster City, CA, USA). For each individual DNA sample,
6 ng of genomic DNA was amplified in a total volume of 5
μl containing both allele probes labeled with 5'-VIC or 5'-
FAM fluorophore and 2.5 μl of TaqMan® universal PCR
master mix. Amplification reaction conditions were 10
min at 95°C, followed by 50 cycles of 95°C for 15 sec and
60°C for 1.5 min. Allelic discrimination analysis was per-
formed on the Prism 7900HT Fast Real-Time PCR system
using the software SDSv2.2.2 (Applied Biosystems, Foster
City, CA, USA). Quality criteria of genotyping were as
follows: Minor allele frequency 0.412, call rate 100%, test
for deviation from Hardy Weinberg Equilibrium p =
0.707.
Paradigm
Sixty laser stimuli were applied to the dorsum of the left
hand using a Thulium: YAG laser (Baasel Lasertech) with
a wavelength of 2000 nm as described previously by sev-
eral groups including our own [33,39-41]. Stimuli were
applied from a distance of 3 cm at a 90° angle. The site of
the stimulation was manually moved after each trial to
avoid tissue damage. Pulse duration was 1 ms, stimuli
were spots 6 mm in diameter, stimulus intensity was 600
mJ. The interval between stimuli was pseudo-random-
ized between 8-12 seconds. Every third laser-stimulus in
the sequence was skipped to allow the hemodynamic
response return to baseline. At the end of the experiment
subjects were asked to rate verbally the perceived sensa-
tion on a numerical rating scale ranging from 0 to 100
where 0 was "no pain" and 100 "pain as bad as it could be"
[42]. Laser stimuli elicited a clear pinprick sensation in all
57 subjects. The post-hoc average pain rating was 42.1
Figure 2 Boxplot of COMT genotype effect on fMRI BOLD activa-
tion in the anterior cingulate cortex (ACC). Median, 25th percentile, 
75th percentile, minimum value, maximum value and outliers are 
shown. 1 The high BOLD activation in response to laser stimulation in 
this subject was reproduced in a second experiment that was per-
formed two month later (mean Z value in the ACC = 5.3), suggesting 
that this 'outlier' is reflecting biological variance in the sample and not 
a measurement error. Furthermore, the genotype effect on ACC activa-
tion remained significant, (F = 7.06; p = 0.01; F = 4.92; p = 0.031 age-
corrected) even when this subject was excluded from the analysis.
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cal data (electroencephalography (EEG) and electroder-
mal activity (EDA)) were simultaneously obtained but
were not considered for the present analysis.
fMRI data acquisition
Functional MR-images were acquired using a 3T scanner
(Trio, Siemens, Erlangen, Germany). In order to avoid
head movements, the head of each subject was tightly fix-
ated during the scanning procedure with vacuum cush-
ions and sponge pads. Using echo planar imaging (EPI),
350 volumes were obtained applying the following EPI
parameters: 44 slices, no gap, slice thickness 3 mm, FOV
192 × 192 mm, matrix 64 × 64, repetition time 2,670 ms,
echo time 30 ms, flip angle 90°. To facilitate localization
and co-registration of functional data, structural scans
were acquired using T1-weighted MRI sequences (Mag-
netization prepared rapid gradient echo (MP-RAGE):
TR/TE = 1,700/3.5 ms, flip angle = 9°, 208 sagittal slices,
FOV 240 × 195 mm, matrix 320 × 260, voxel size 0.75 ×
0.75 × 0.75 mm.
fMRI analysis
fMRI-analysis was performed with FSL (FMRIB's Soft-
ware Library, http://www.fmrib.ox.ac.uk/fsl). The follow-
ing pre-processing procedure was applied: Employing
different modules of the FSL-software package, we con-
ducted motion correction using MCFLIRT [43], non-
brain removal using BET [44], spatial smoothing using a
Gaussian kernel of FWHM = 6 mm, mean-based inten-
sity normalization of all volumes by the same factor, and
highpass temporal filtering (sigma = 30 seconds). Whole
brain general linear model (GLM) time-series statistical
analysis of individual data sets was carried out using
FILM (FMRIB's Improved Linear Model) with local auto-
correlation correction [45]. Registration of functional
images to high resolution structural images was done
with FLIRT [43,46]. For the analysis of functional data, we
used the time course of laser stimuli as the explanatory
variable (EV) convolved with a Double-Gamma hemody-
namic response function. The Double-Gamma function
is a mixture of two Gamma functions - a standard posi-
tive function at normal lag (6 seconds) and a small
delayed, inverted Gamma to model the late undershoot
[47].
Group level mixed effect analyses were conducted
using FLAME (FMRIB's Local Analysis of Mixed Effects)
[48] with spatial normalization to MNI (Montreal Neuro-
logical Institute) space and applying a cluster significance
threshold of Z > 2.3 [46,49,50]. Differences between gen-
otype groups were investigated using two sample t-tests.
For visual display of the group results, Z-maps of the
functional data were imported to MRIcron [51].
fMRI genotype effect analysis
Given the sample size of the present study, we primarily
adopted a region-of-interest (ROI) approach for the anal-
ysis of genotype effects in order to reduce the degrees of
freedom in the data space. For ROI analyses four anatom-
ical masks were created (Fig. 3): a) bilateral parietal oper-
cular cortex containing the secondary somatosensory
cortex (S2) b) bilateral insula and c) bilateral anterior cin-
gulate cortex (ACC), d) bilateral amygdala. These regions
were chosen because they are known to be key areas of
cortical pain processing, often referred to as the 'pain
matrix' or important interconnected structures [5,6]. The
masks were created using the Harvard Oxford atlas tool
for cortical and subcortical structures which is imple-
mented in the FSL software package. Within the resulting
ROIs, the mean Z-value was calculated. These masks
were also used for small-volume correction of group-level
mixed-effects FLAME analysis of activation differences
between COMT genotype groups. Here, differences
between genotype groups were investigated using two
sample t-tests.
Statistical analysis
All statistical analyses were performed using the SPSS 15
software package (SPSS Inc. Chicago, Il, USA). Two-sam-
ple t-tests or chi-square tests were used as appropriate to
determine the statistical significance of differences in
demographic variables between genotype groups. The
Table 3: Demographic data
COMT Genotype group Statistical significance of group differences
met/met
N = 19
val carriers
N = 38
Males/females 12/7 15/23 (χ2 = 2.85; p = 0.091)
Smokers/Non-smokers 7/12 17/21 (χ2 = 0.32; p = 0.569)
Mean age (years)/SD 31.6/11.0 37.2/10.9 (t = 1.80; p = 0.077)
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ences in fMRI region-of-interest activation measures was
tested using a multivariate GLM analysis of variance
(MANOVA) with COMT genotype as factor, and mean
Z-values in the four ROIs as dependent variables. Subse-
quent "post-hoc" analyses of variance (ANOVAs) for each
of the four ROIs separately were also performed.
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